DaVita (NYSE:DVA) Price Target Raised to $250.00 at Truist Financial

DaVita (NYSE:DVA) had its price target upped by Truist Financial from $205.00 to $250.00 in a report issued on Tuesday, MarketBeat reports. Truist Financial currently has a hold rating on the stock.

DVA has been the subject of several other reports. Deutsche Bank Aktiengesellschaft upgraded DaVita from a “hold” rating to a “buy” rating and upped their target price for the stock from $126.00 to $220.00 in a report on Wednesday, May 6th. Barclays lifted their price objective on DaVita from $194.00 to $218.00 and gave the company an “equal weight” rating in a report on Wednesday, July 8th. Zacks Research lowered shares of DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. TD Cowen increased their target price on shares of DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a report on Monday, May 11th. Finally, UBS Group raised their target price on shares of DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research report on Friday. Two investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, DaVita currently has an average rating of “Hold” and an average target price of $216.50.

DaVita Price Performance

Shares of DVA stock opened at $232.46 on Tuesday. The company has a market capitalization of $14.92 billion, a P/E ratio of 21.56, a P/E/G ratio of 0.77 and a beta of 0.88. The company’s 50-day simple moving average is $207.62 and its two-hundred day simple moving average is $162.31. DaVita has a one year low of $101.00 and a one year high of $239.64.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The firm had revenue of $3.42 billion during the quarter, compared to analyst estimates of $3.36 billion. During the same quarter in the previous year, the business earned $2.00 earnings per share. DaVita’s quarterly revenue was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, research analysts expect that DaVita will post 15.07 EPS for the current fiscal year.

Insider Activity at DaVita

In related news, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the completion of the transaction, the insider owned 109,194 shares in the company, valued at $22,756,029.60. The trade was a 12.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Joel Ackerman sold 51,471 shares of the firm’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the completion of the sale, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at approximately $25,440,571.40. This represents a 27.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.90% of the company’s stock.

Institutional Trading of DaVita

A number of institutional investors have recently bought and sold shares of the stock. Nordea Investment Management AB boosted its holdings in DaVita by 18.0% in the 4th quarter. Nordea Investment Management AB now owns 338,192 shares of the company’s stock worth $38,321,000 after buying an additional 51,607 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S raised its holdings in shares of DaVita by 63.5% during the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 86,000 shares of the company’s stock valued at $9,770,000 after acquiring an additional 33,394 shares during the last quarter. SG Americas Securities LLC raised its holdings in shares of DaVita by 27.4% during the first quarter. SG Americas Securities LLC now owns 212,293 shares of the company’s stock valued at $32,627,000 after acquiring an additional 45,609 shares during the last quarter. Los Angeles Capital Management LLC lifted its position in shares of DaVita by 132.2% in the fourth quarter. Los Angeles Capital Management LLC now owns 24,322 shares of the company’s stock valued at $2,888,000 after acquiring an additional 13,847 shares in the last quarter. Finally, M&T Bank Corp boosted its stake in shares of DaVita by 694.7% in the fourth quarter. M&T Bank Corp now owns 22,307 shares of the company’s stock worth $2,534,000 after acquiring an additional 19,500 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.